NSPR on Nasdaq

InspireMD, Inc.

American surgical and medical instruments and apparatus company based in Miami. Summary from the record

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with NEUROONE MEDICAL TECHNOLOGIES Corp, Medinotec Inc. or WORK Medical Technology Group LTD, or pick any stock.

  • TickerNSPR on Nasdaq2
  • IndustrySurgical & Medical Instruments & Apparatus2
  • HeadquartersBoston, United States2
  • Incorporated inDE3
  • Business address6303 Waterford District Drive, Suite 215, Miami, Fl 331263
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI549300OQ16IJ5DIS5D302
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O The Corporation Trust Company, 19801 Wilmington, United States2

See how the biggest companies compare on our leaderboards

Administration (“FDA”) on June 23, 2025, and is marketed exclusively in the United States through our direct salesforce.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

29.5%Gross margin5
-552.6%Operating margin5
-543.3%Net margin5
28.1%Revenue growth, 20255
-88.4%Return on equity5
-$36.8MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Regions

Other Countries brought in 45% of the revenue InspireMD, Inc. broke down this way in fiscal 2025.

  1. Other Countries$4.1M545%up 19% from 2024
  2. United States$1.4M516%up 4328% from 2024
  3. DEMember$1.2M514%up 33% from 2024
  4. Italy$1.2M514%up 1% from 2024
  5. PL$1.0M512%up 49% from 2024
Regions by year
Regions20242025
Other Countries$3.4M$4.1M
United States$32.0K$1.4M
DEMember$926.0K$1.2M
Italy$1.2M$1.2M
PL$694.0K$1.0M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue30¢$6.3M
  • Research and development70¢$15.0M
  • Income tax0¢$63.0K

Out of $9.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$9.0M in 2025+141% since 2019
0$2.5M$5.0M$7.5M$10.0M2019: $3.7M$3.7M20192020: $2.5M$2.5M2020−33%2021: $4.5M$4.5M2021+81%2022: $5.2M$5.2M2022+15%2023: $6.2M$6.2M2023+20%2024: $7.0M$7.0M2024+13%2025: $9.0M$9.0M2025+28%
Gross profit6789105$2.6M in 2025+250% since 2019
0$1.0M$2.0M$3.0M2019: $756.0K$756.0K20192020: $83.0K$83.0K2020−89%2021: $754.0K$754.0K2021+808%2022: $1.1M$1.1M2022+48%2023: $1.8M$1.8M2023+62%2024: $1.5M$1.5M2024−17%2025: $2.6M$2.6M2025+76%
Operating income6789105-$49.6M in 2025+405% since 2019
-$60.0M-$40.0M-$20.0M02019: -$9.8M-$9.8M20192020: -$10.4M-$10.4M2020+6%2021: -$14.7M-$14.7M2021+42%2022: -$18.7M-$18.7M2022+27%2023: -$21.1M-$21.1M2023+13%2024: -$33.5M-$33.5M2024+58%2025: -$49.6M-$49.6M2025+48%
Net income6789105-$48.8M in 2025+386% since 2019
-$60.0M-$40.0M-$20.0M02019: -$10.0M-$10.0M20192020: -$10.5M-$10.5M2020+5%2021: -$14.9M-$14.9M2021+41%2022: -$18.5M-$18.5M2022+24%2023: -$19.9M-$19.9M2023+8%2024: -$32.0M-$32.0M2024+61%2025: -$48.8M-$48.8M2025+52%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
REVENUES$9.0M$7.0M
COST OF REVENUES$6.3M$5.5M
GROSS PROFIT$2.6M$1.5M
Research and development$15.0M$13.6M
Selling and marketing$16.6M$6.1M
General and administrative$20.7M$15.3M
Total operating expenses$52.3M$35.0M
LOSS FROM OPERATIONS-$49.6M-$33.5M
FINANCIAL INCOME, net:$891.0K$1.6M
LOSS BEFORE TAX EXPENSES-$48.7M-$31.9M
TAX EXPENSES$63.0K$59.0K
NET LOSS-$48.8M-$32.0M
NET LOSS PER SHARE - basic-$0.76-$0.76
NET LOSS PER SHARE - diluted-$0.76-$0.76
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic64.3M shares41.9M shares
WEIGHTED AVERAGE NUMBER OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted64.3M shares41.9M shares

Compare InspireMD, Inc. with another company

Leadership

Who has led InspireMD, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ofir Paz2011
  2. Alan Milinazzo2013–2016
  3. Marvin Slosman2020–now

President

  1. Asher Holzer2011
  2. Alan Milinazzo2013–2016
  3. Marvin Slosman2020–now

Chief financial officer

  1. Craig Shore2011–2025
  2. Michael A. Lawless2025–now

Chief operating officer

  1. Andrea Tommasoli2023–now
201520202025
Board members and other officers (21)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive OfficerPete Ligotti named Aug 4, 202537
  • DirectorMichael Berman named May 30, 2023 to Aug 4, 202537

Former names

  • Saguaro Resources, Inc.Sep 28, 2009 to Apr 1, 20113

Timeline

  1. Jan 3, 2020New chief executive Marvin Slosman becomes CEO13
  2. Jan 7, 2013New chief executive Alan Milinazzo becomes CEO14
  3. Apr 5, 2011New chief executive Ofir Paz becomes CEO15

Filings

296 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 74 major events, 119 insider forms, 38 large holders, 2 private raises, 43 other. The latest 20:

  1. Sep 23, 20264 EDGAR
  2. Sep 23, 20264 EDGAR
  3. Sep 23, 20264 EDGAR
  4. Sep 21, 20268-K EDGAR
  5. Aug 17, 20268-K EDGAR
  6. Aug 14, 202610-Q EDGAR
  7. Jul 29, 20268-K EDGAR
  8. Jul 23, 20268-K EDGAR
  9. Jul 2, 20268-K EDGAR
  10. Jun 11, 20268-K EDGAR
  11. Jun 3, 20268-K EDGAR
  12. May 29, 20264 EDGAR
  13. May 22, 20268-K EDGAR
  14. May 21, 20264 EDGAR
  15. May 15, 20264 EDGAR
  16. May 15, 2026SCHEDULE 13G/A EDGAR
  17. May 15, 2026SCHEDULE 13G/A EDGAR
  18. May 13, 20264 EDGAR
  19. May 13, 20264/A EDGAR
  20. May 12, 20264 EDGAR

The 296 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

61 open-market trades by officers, directors and large owners since October 2021: 37 buys and 24 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
May 27, 2026Stuka PaulDirectorBuy20,000$0.88$17.6KForm 4
May 19, 2026Gleason Shane ThomasChief Commercial OfficerSale22,778$1.01$23.0KForm 4
May 14, 2026Stuka PaulDirectorBuy5,000$1.15$5.8KForm 4
May 13, 2026Stuka PaulDirectorBuy10,000$1.16$11.6KForm 4
May 12, 2026Slosman MarvinCEO and PresidentBuy21,000$1.20$25.2KForm 4
May 11, 2026Stuka PaulDirectorBuy10,000$1.19$11.9KForm 4
May 11, 2026Stuka PaulDirectorBuy10,000$1.19$11.9KForm 4
May 8, 2026Stuka PaulDirectorBuy65,626$1.16$76.1KForm 4
May 8, 2026Stuka PaulDirectorBuy65,626$1.16$76.1KForm 4
May 7, 2026Ward Scott R.DirectorBuy73,255$1.15$84.2KForm 4
May 7, 2026Stuka PaulDirectorBuy6,378$1.15$7.3KForm 4
May 7, 2026ROUBIN GARY SDirectorBuy90,000$1.18$106.2KForm 4
May 6, 2026Ward Scott R.DirectorBuy15,995$1.15$18.4KForm 4
May 6, 2026Stuka PaulDirectorBuy1,517$1.12$1.7KForm 4
Feb 2, 2026Gleason Shane ThomasChief Commercial OfficerSale2,941$1.59$4.7KForm 4
Feb 2, 2026Gleason Shane ThomasChief Commercial OfficerSale2,000$1.60$3.2KForm 4
Jan 30, 2026Gleason Shane ThomasChief Commercial OfficerSale2,900$1.63$4.7KForm 4
Jan 29, 2026Gleason Shane ThomasChief Commercial OfficerSale5,000$1.65$8.2KForm 4
Jan 28, 2026Gleason Shane ThomasChief Commercial OfficerSale12,395$1.65$20.5KForm 4
Jan 27, 2026Gleason Shane ThomasChief Commercial OfficerSale4,781$1.66$7.9KForm 4

All 61 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Jul 30, 2025Raised $40.1 million in a private offering of equity Form D: 18 investors so far Form D
  2. May 12, 2023Raised $42.2 million in a private offering of equity Form D: 18 investors so far Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 37. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Nantahala Capital Management, LLC6,752,968$4.7M0.1%+3,376,484
Rosalind Advisors, Inc.3,905,743$2.7M1.0%No change
Aberdeen Group plc3,698,364$2.6M0.0%+525,000
Orbimed Advisors LLC3,133,405$2.2M0.0%No change
Parkman Healthcare Partners LLC2,416,518$1.7M0.2%No change
Marshall Wace, Llp1,860,405$1.3M0.0%No change
Soleus Capital Management, L.P.1,045,708$732.1K0.0%No change
Pura Vida Investments, LLC450,517$315.4K0.9%No change
Affiance Financial, LLC250,370$175.3K0.0%No change
Velan Capital Investment Management LP148,138$103.7K0.1%−1,951,514
BlackRock, Inc.122,993$86.1K0.0%+42,544
Renaissance Technologies LLC112,832$79.0K0.0%+95,223
Creative Planning108,964$76.3K0.0%+89,250
Schonfeld Strategic Advisors LLC99,275$69.5K0.0%New
XTX Topco Ltd49,029$34.3K0.0%+36,671
Centiva Capital, LP44,123$30.9K0.0%+19,357
Millennium Management LLC37,677$26.4K0.0%−74,746
Courier Capital LLC30,000$21.0K0.0%No change
Mesirow Financial Investment Management, Inc.30,000$21.0K0.0%No change
Morgan Stanley28,371$19.9K0.0%−11,465
Vestia Personal Wealth Advisors24,425$17.1K0.0%No change
Susquehanna International Group, Llp20,594$14.4K0.0%New
LPL Financial LLC18,621$13.0K0.0%New
Osaic Holdings, Inc.15,952$11.2K0.0%+5,500
Avestar Capital, LLC15,000$10.5K0.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51